Search results for "treatment failure"

showing 10 items of 114 documents

Reoperation Rates Following Instrumented Lumbar Spine Fusion

2018

Study Design. A prospective cohort study. Objective. This study evaluated the cumulative reoperation rate and indications for reoperation following instrumented lumbar spine fusion (LSF). Summary of Background Data. LSF reduces disability and improves health-related quality of life for patients with several spinal disorders. The rate of instrumented LSF has drastically increased over the last few decades. The increased incidence of LSF, however, has led to increased reoperation rates. Methods. The data are based on the prospective LSF database of Tampere University Hospital that includes all elective indications for LSF surgery. A total of 433 consecutive patients (64% women, mean age 62 ye…

AdultMaleReoperationmedicine.medical_specialtycomplicationssurgical treatmentmedicine.medical_treatmentreoperationadjacent segmentKaplan-Meier EstimateleikkaushoitolannerankaYoung Adult03 medical and health sciences0302 clinical medicineQuality of lifeHumansMedicineOrthopedics and Sports MedicineCumulative incidenceProspective StudiesTreatment Failure030212 general & internal medicineYoung adultortopediaProspective cohort studySurvival rateAgedta3126Aged 80 and overinstrumented lumbar spine fusionLumbar Vertebraebusiness.industryIncidence (epidemiology)ta3141komplikaatiotMiddle AgedConfidence intervalProsthesis FailureSurgerySpinal FusionSpinal fusionorthopedicsFemaleSpinal DiseasesNeurology (clinical)business030217 neurology & neurosurgerySpine
researchProduct

Predicting the failure in distal femur fractures.

2018

Abstract Introduction The incidence of nonunion after fractures of the distal femur is up to 6%. The distal femoral nonunion is a disabling disease that needs complex steps in his treatment. Aim of our study is to find predicting factors of non-unions. Materials and methods We retrospectively analyzed 116 cases of distal femoral fractures and 20 cases of non-unions. In both surgeries we analyzed: accuracy of reduction, stability of fixation, hardware used, residual medial or lateral bone defect, use of autologous or heterologous bone grafts. Results Malreduction, particularly axial defect, associated with unbalanced fixation, and a medial cortical bone defect of greater or lesser extent wer…

AdultMaleReoperationmedicine.medical_specialtymedicine.medical_treatmentNonunionBone graftingNon union03 medical and health sciencesDistal femurFracture Fixation InternalYoung Adult0302 clinical medicinePostoperative ComplicationsmedicineHumans030212 general & internal medicineTreatment FailureRange of Motion ArticularReduction (orthopedic surgery)General Environmental ScienceFixation (histology)AgedRetrospective StudiesFracture Healing030222 orthopedicsBone Transplantationbusiness.industryMiddle AgedBone defectmedicine.diseaseSurgeryBiomechanical Phenomenasurgical procedures operativemedicine.anatomical_structureFractures UnunitedGeneral Earth and Planetary SciencesCortical boneFemalebusinessBone PlatesFemoral FracturesInjury
researchProduct

Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplant…

2001

We investigated whether a T cell-reduced allogeneic stem cell transplant (SCT) with minimal conditioning and subsequent donor lymphocyte infusions (DLI) could reduce the incidence and severity of GVHD while retaining stable engraftment. Five patients with hematological malignancies (three MM, one CLL, one Chediak-Higashi syndrome) were conditioned with TBI (200 cGy). One patient additionally received fludarabine (120 mg/m(2)). CsA and mofetyl-mycophenolate (MMF) were administered to prevent GVHD. All patients were grafted with >3 x 10(6)/kg highly purified CD34(+) cells together with 2 x 10(6)/kg CD3(+) cells (three patients) or 1 x 10(5)/kg CD3(+) cells (two patients). Quick hematopoietic …

AdultMaleTime FactorsLymphocyte TransfusionT-LymphocytesT cellLymphocyteChronic lymphocytic leukemiamedicine.medical_treatmentHematopoietic stem cell transplantationLymphocyte DepletionFatal OutcomemedicineHumansTransplantation HomologousTreatment FailureTransplantation ChimeraTransplantationbusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle AgedMycophenolic Acidmedicine.diseaseLeukemia Lymphocytic Chronic B-CellPeripheral stem cell transplantationFludarabineTransplantationmedicine.anatomical_structureHematologic NeoplasmsLymphocyte TransfusionImmunologyCyclosporineFemaleChediak-Higashi SyndromeMultiple MyelomabusinessImmunosuppressive AgentsVidarabineWhole-Body IrradiationFollow-Up Studiesmedicine.drugBone Marrow Transplantation
researchProduct

Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy

2014

Abstract Background Infliximab is effective as rescue therapy in severe corticosteroid-refractory ulcerative colitis. The optimal dose regimen and the long term benefits are not well defined. The aim of the present study was to evaluate short- and long-term colectomy rate in a cohort of patients with severe corticosteroid-refractory ulcerative colitis who received a three-dose infliximab induction regimen. Methods One hundred and thirteen patients admitted to 11 Italian IBD referral centres and treated with infliximab according to an intention to treat three-dose regimen were included. The co-primary endpoints were 3- and 12-month colectomy rate. The secondary end-points were the overall co…

AdultMalemedicine.medical_specialtyAdolescentSettore MED/12 - GASTROENTEROLOGIAmedicine.medical_treatmentUlcerative colitis;GastroenterologyDrug Administration ScheduleYoung AdultAdrenal Cortex HormonesInternal medicineHumansMedicineTreatment FailureAdverse effectColectomyInfliximab;AgedColectomyIntention-to-treat analysisbusiness.industryAnti-Inflammatory Agents Non-SteroidalGastroenterologyAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseUlcerative colitisInfliximabInfliximabRegimenTreatment OutcomeUlcerative colitisRelative riskCohortColitis UlcerativeFemalebusinessmedicine.drugJournal of Crohn's and Colitis
researchProduct

Oxidative stress markers in the neocortex of drug-resistant epilepsy patients submitted to epilepsy surgery

2013

Summary Purpose While there is solid experimental evidence of brain oxidative stress in animal models of epilepsy, it has not been thoroughly verified in epileptic human brain. Our purpose was to determine and to compare oxidative stress markers in the neocortex of epileptic and non-epileptic humans, with the final objective of confirming oxidative stress phenomena in human epileptic brain. Methods Neocortical samples from drug-resistant epilepsy patients submitted to epilepsy surgery ( n =20) and from control, non-epileptic cortex samples ( n =11) obtained from brain bank donors without neurological disease, were studied for oxidative stress markers: levels of reactive oxygen species (ROS)…

AdultMalemedicine.medical_specialtyGlutathione reductaseNeocortexBiologymedicine.disease_causeLipid peroxidationSuperoxide dismutasechemistry.chemical_compoundEpilepsyInternal medicinemedicineHumansTreatment Failurechemistry.chemical_classificationGlutathione PeroxidaseReactive oxygen speciesEpilepsySuperoxide DismutaseGlutathione peroxidaseMiddle AgedCatalasemedicine.diseasePsychosurgeryOxidative StressGlutathione ReductaseEndocrinologyNeurologyBiochemistrychemistryCatalaseRetreatmentbiology.proteinAnticonvulsantsFemaleNeurology (clinical)BiomarkersOxidative stressEpilepsy Research
researchProduct

Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study.

2021

OBJECTIVE To describe the efficacy and safety of biologics for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA). METHODS A retrospective European collaborative study was conducted in patients with EGPA who received treatment with biologics for refractory and/or relapsing disease. RESULTS Among the 147 patients with EGPA included in the study, 63 received rituximab (RTX), 51 received mepolizumab (MEPO), and 33 received omalizumab (OMA). At the time of inclusion, the median Birmingham Vasculitis Activity Score (BVAS) was 8.5 (interquartile range [IQR] 5-13) in the RTX group, while the median BVAS in the OMA group was 2 (IQR 1-4.5) and the median BVAS in the MEPO group was…

AdultMalemedicine.medical_specialtyImmunologyBirmingham Vasculitis Activity ScoreOmalizumabOmalizumabChurg-Strauss SyndromeAntibodies Monoclonal Humanized03 medical and health sciences0302 clinical medicineRheumatologyInterquartile rangeRecurrenceInternal medicinemedicineImmunology and AllergyHumansImmunologic Factors030212 general & internal medicineTreatment FailureAdverse effectGlucocorticoidsAgedRetrospective Studies030203 arthritis & rheumatologyBiological Productsbusiness.industryMiddle Agedmedicine.diseaseAsthmaTreatment OutcomeRituximabFemaleVasculitisbusinessGranulomatosis with polyangiitisRituximabMepolizumabmedicine.drugArthritisrheumatology (Hoboken, N.J.)References
researchProduct

Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Si…

2020

BACKGROUND AND OBJECTIVE: Older people with inflammatory bowel disease (IBD) appear to have a lower response to anti-tumour necrosis factor (TNF) therapy, with more frequent complications than younger patients. The objective of this study was to assess persistence on therapy and the safety of anti-TNF therapy in older patients (aged ≥ 60 years). METHODS: We retrospectively reviewed the database of the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD), extracting data regarding IBD patients aged ≥ 60 years and controls < 60 years of age at their first course of anti-TNF treatment. Data concerning persistence on therapy over the first year of treatment (primary objective) together …

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaDrug-Related Side Effects and Adverse ReactionsKaplan-Meier EstimateAnti-Tumour Necrosis FactorDiseaseInflammatory bowel diseaseCohort Studies03 medical and health sciences0302 clinical medicinePharmacotherapyInternal medicinemedicineHumansPharmacology (medical)Treatment Failure030212 general & internal medicineAdverse effectAgedRetrospective StudiesAged 80 and overTumor Necrosis Factor-alphabusiness.industryInflammatory Bowel DiseaseAdalimumabAge FactorsAntibodies MonoclonalRetrospective cohort studyMiddle AgedInflammatory Bowel Diseasesmedicine.diseaseUlcerative colitisInfliximabSicilian Network for Inflammatory Bowel Diseases (SN-IBD).Withholding TreatmentConcomitantFemaleGeriatrics and Gerontologybusiness030217 neurology & neurosurgeryCohort studyDrugs & Aging
researchProduct

Acute Phase Proteins Are Baseline Predictors of Tuberculosis Treatment Failure

2021

Systemic inflammation is a characteristic feature of pulmonary tuberculosis (PTB). Whether systemic inflammation is associated with treatment failure in PTB is not known. Participants, who were newly diagnosed, sputum smear and culture positive individuals with drug-sensitive PTB, were treated with standard anti-tuberculosis treatment and classified as having treatment failure or microbiological cure. The plasma levels of acute phase proteins were assessed at baseline (pre-treatment). Baseline levels of C-reactive protein (CRP), alpha-2 macroglobulin (a2M), Haptoglobin and serum amyloid P (SAP) were significantly higher in treatment failure compared to cured individuals. ROC curve analysis …

AdultMalemedicine.medical_specialtyTuberculosisImmunologyAntitubercular AgentsSystemic inflammationGastroenterologyCohort StudiesInternal medicinemedicineHumansImmunology and AllergyProspective StudiesTreatment FailureTuberculosis PulmonaryOriginal ResearchHaptoglobinsbiologybusiness.industryHaptoglobinAcute-phase proteinArea under the curveRC581-607Middle Agedmedicine.diseasePregnancy-Associated alpha 2-MacroglobulinsMacroglobulinSerum Amyloid P-ComponentC-Reactive ProteintuberculosisROC CurveinflammationTB treatmentacute phase proteinsbiology.proteinbiomarkerSputumBiomarker (medicine)FemaleImmunologic diseases. Allergymedicine.symptombusinessBiomarkersAcute-Phase ProteinsFrontiers in Immunology
researchProduct

Outcomes of uvulopalatopharyngoplasty with harmonic scalpel after failure of continuous positive airway pressure in sleep apnea syndrome.

2012

Our data highlight that uvulopalatopharyngoplasty (UPPP) with harmonic scalpel (HS) is a reliable treatment in selected patients affected by obstructive sleep apnea (OSA) and users of continuous positive airway pressure (CPAP).The aim of this paper was to verify the efficacy and applicability of UPPP with HS in the treatment of patients affected by OSA and users of CPAP.A total of 21 patients with a retropalatal obstruction and users of CPAP underwent UPPP with HS and were evaluated (before and 6 months after surgery) using the apnea/hypopnea index (AHI); oxygen desaturation index ≥4% (ODI(4)); Epworth Sleepiness Scale (ESS); snoring level (SL); subjective assessment of the postoperative pa…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentPostoperative painstomatognathic systemUltrasonic Surgical ProceduresmedicineHumansContinuous positive airway pressureTreatment FailureOxygen desaturation indexAgedSleep Apnea ObstructiveEpworth Sleepiness Scale; Obstructive sleep apnea; Oxygen desaturation index; Postoperative painContinuous Positive Airway Pressurebusiness.industryEpworth Sleepiness ScaleUvulopalatopharyngoplastySleep apneaApneaGeneral MedicineMiddle Agedmedicine.diseaseEpworth Sleepiness ScaleObstructive sleep apneaapnea/hypopnea indexnervous system diseasesrespiratory tract diseasesSurgeryObstructive sleep apneaOtorhinolaryngologyApnea–hypopnea indexUvulaAnesthesiaObstructive sleep apnea; apnea/hypopnea index; oxygen desaturation index; Epworth Sleepiness Scale; postoperative painPharynxFemalemedicine.symptomPalate SoftbusinessHypopneaActa oto-laryngologica
researchProduct

Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combin…

2010

There is a lack of information on the characteristics of patients with chronic hepatitis C virus infection (HCV) who fail to respond to antiviral treatment. We studied HCV-positive subjects with chronic liver diseases treated with pegylated-interferon (PEG-IFN) and ribavirin (RBV) who failed to clear HCV in routine clinical practice. A total of 2150 consecutive adult patients treated with PEG-IFN plus RBV therapy in 46 Italian centres between 1 July 2004, and 30 June 2005, were studied. Of the 2150 patients, 923 (42.9%) (M/F 585/335, mean age 54.8 years) failed to achieve a serum HCV-RNA clearance. Of these 923 patients, 429 (46.5%) were nonresponders, 298 (32.3%) relapsers, 168 (18.2%) dro…

AdultMalenon-responders.relapserGenotypebody mass index; cirrhosis; hepatitis c virus; nonresponder; pegylated-interferon; relapserInfectious Diseasebody mass indexHepacivirusvirusInterferon alpha-2Antiviral AgentsPolyethylene GlycolPolyethylene GlycolsMedication Adherencebody mass index; cirrhosis; hepatitis C; virus; nonresponder; pegylated-interferon; relapserRisk FactorsRetrospective StudienonresponderVirologyRibavirinHumansAge FactorTreatment FailureRetrospective StudiesAgedAntiviral AgentSettore MED/12 - GastroenterologiaHCV; Antiviral therapy; Body mass index; Cirrhosis; Hepatitis C virus; Nonresponder; Pegylated-interferon; RelapserCirrhosiHepaciviruHepatologyRisk FactorcirrhosisAge FactorsInterferon-alphahepatitis c virusHepatitis C ChronicMiddle AgedRecombinant ProteinRecombinant ProteinsItalyRNA ViralFemalehepatitis Cpegylated-interferonHepatitis C viruHuman
researchProduct